Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy

Status: Active, not recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Vitiligo is a chronic acquired cutaneous disease of pigmentation that affects patients' quality of life across all degrees of involvement and severity. Phototherapy, such as Narrow band UVB (NB-UVB), is a clinically indicated treatment for skin lesions. NB-UVB treatment has been shown to promote repigmentation and normalize cellular behaviors. The investigators would like to analyze the change in protein expression and histological change in skin from NB-UVB treatment in participants with Vitiligo. The investigators are recruiting participants with Vitiligo on the body, arms, and/or legs.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: Accepts Healthy Volunteers
View:

• Adults 18 years or older with bilateral symmetrical vitiligo lesions, in general good health as determined by the Principal Investigator by medical history and physical exam.

• Able to understand consent procedure

• Able to comply with protocol activities

Locations
United States
Maryland
Johns Hopkins Outpatient Center
Baltimore
Time Frame
Start Date: October 1, 2017
Estimated Completion Date: September 1, 2024
Participants
Target number of participants: 20
Treatments
Experimental: Phototherapy (NB-UVB)
Phototherapy (NB-UVB) will be administered for all enrolled subjects. The starting dosage will be 250 mJ/cm2. The dose will be increased by 10% with each treatment, as long as there are no side effects with treatment.
Sponsors
Leads: Johns Hopkins University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials